Free Trial

Cogent Biosciences (COGT) Competitors

$8.22
+0.73 (+9.75%)
(As of 05/24/2024 04:00 PM ET)

COGT vs. CVAC, WVE, ANAB, NUVB, SAGE, GHRS, CALT, NRIX, PAHC, and AUPH

Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include CureVac (CVAC), Wave Life Sciences (WVE), AnaptysBio (ANAB), Nuvation Bio (NUVB), Sage Therapeutics (SAGE), GH Research (GHRS), Calliditas Therapeutics AB (publ) (CALT), Nurix Therapeutics (NRIX), Phibro Animal Health (PAHC), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.

Cogent Biosciences vs.

CureVac (NASDAQ:CVAC) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership.

CureVac has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Cogent Biosciences has a net margin of 0.00% compared to Cogent Biosciences' net margin of -463.49%. Cogent Biosciences' return on equity of -49.22% beat CureVac's return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac-463.49% -49.22% -33.85%
Cogent Biosciences N/A -91.56%-55.20%

In the previous week, CureVac had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for CureVac and 8 mentions for Cogent Biosciences. CureVac's average media sentiment score of 0.31 beat Cogent Biosciences' score of 0.31 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CureVac
2 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Cogent Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cogent Biosciences received 252 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 70.62% of users gave Cogent Biosciences an outperform vote while only 51.16% of users gave CureVac an outperform vote.

CompanyUnderperformOutperform
CureVacOutperform Votes
22
51.16%
Underperform Votes
21
48.84%
Cogent BiosciencesOutperform Votes
274
70.62%
Underperform Votes
114
29.38%

17.3% of CureVac shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CureVac currently has a consensus target price of $8.33, indicating a potential upside of 125.84%. Cogent Biosciences has a consensus target price of $14.67, indicating a potential upside of 78.43%. Given Cogent Biosciences' higher probable upside, equities analysts plainly believe CureVac is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cogent Biosciences
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Cogent Biosciences has lower revenue, but higher earnings than CureVac. Cogent Biosciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$58.18M14.20-$281.58M-$1.28-2.88
Cogent BiosciencesN/AN/A-$192.41M-$2.48-3.31

Summary

CureVac beats Cogent Biosciences on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COGT vs. The Competition

MetricCogent BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$785.91M$6.61B$4.89B$8.02B
Dividend YieldN/A2.77%5.26%3.96%
P/E Ratio-3.3110.81121.0314.78
Price / SalesN/A248.522,548.2775.59
Price / CashN/A20.3132.0728.77
Price / Book3.575.854.944.46
Net Income-$192.41M$136.83M$102.06M$212.61M
7 Day Performance4.85%4.08%2.56%1.21%
1 Month Performance36.54%7.68%6.92%5.87%
1 Year Performance-26.80%-2.01%7.73%9.31%

Cogent Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVAC
CureVac
3.3452 of 5 stars
$3.10
+4.4%
$8.33
+168.8%
-59.7%$694.03M$58.18M0.001,172
WVE
Wave Life Sciences
4.6678 of 5 stars
$5.84
+2.6%
$10.14
+73.7%
+69.9%$714.34M$112.91M-11.23266Positive News
ANAB
AnaptysBio
2.0533 of 5 stars
$25.26
+5.3%
$46.38
+83.6%
+28.2%$690.10M$17.16M-4.11117News Coverage
NUVB
Nuvation Bio
3.2356 of 5 stars
$3.31
-1.8%
$6.60
+99.7%
+91.3%$720.66MN/A-9.7251Analyst Forecast
Analyst Revision
SAGE
Sage Therapeutics
4.6055 of 5 stars
$11.99
-1.4%
$37.67
+214.2%
-76.5%$721.58M$91.06M-1.43487Positive News
GHRS
GH Research
0.7047 of 5 stars
$13.02
+1.1%
$36.67
+181.6%
+24.5%$677.43MN/A-21.0049
CALT
Calliditas Therapeutics AB (publ)
1.9437 of 5 stars
$22.59
+7.5%
$34.00
+50.5%
+25.7%$672.96M$113.78M-13.77192Earnings Report
Analyst Forecast
Gap Up
NRIX
Nurix Therapeutics
2.0168 of 5 stars
$14.95
+7.2%
$21.33
+42.7%
+55.0%$734.79M$76.99M-5.62284Gap Up
PAHC
Phibro Animal Health
4.0505 of 5 stars
$18.21
+0.6%
$14.75
-19.0%
+40.5%$737.51M$977.90M56.911,920Analyst Revision
AUPH
Aurinia Pharmaceuticals
2.4992 of 5 stars
$5.20
+3.6%
$10.00
+92.3%
-45.1%$741.83M$175.51M-12.09300

Related Companies and Tools

This page (NASDAQ:COGT) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners